Posted by Michael Wonder on 23 Feb 2017
Celltrion’s Rituxan biosimilar wins European approval
22 February 2017 - Truxima slated to hit European markets in Q2.
South Korea’s Celltrion announced Wednesday that the EMA has granted sales approval to Truxima, its biosimilar drug referencing Roche’s blockbuster lymphatic cancer drug Rituxan.
Truxima is the first ever Rituxan (rituximab) biosimilar to be approved by the European drug regulator, as well as the first ever Europe-approved biosimilar monoclonal antibody used to target cancer.
